Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsSarah Weiss, MD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Assistant Professor (Medical Oncology)
Biography
Sarah A. Weiss, MD, Assistant Professor of Medicine at Yale School of Medicine completed her internship and residency at the Montefiore Medical Center of the Albert Einstein College of Medicine in Bronx, NY and received her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She completed a 3-year fellowship in Hematology and Medical Oncology at New York University School of Medicine and a 1-year post-doctoral fellowship with a focus on tissue-based prognostic markers in melanoma.
Dr. Weiss is a member of both the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer. Some of her ongoing research includes study of new immunotherapeutic strategies for patients with melanoma whose disease has progressed on standard therapy.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
Education & Training
- Post-Docotoral Research Fellowship (Melanoma)
- New York University (2016)
- Fellowship
- New York University (2015)
- Residency
- Montefiore Medical Center of the Albert Einstein College of Medicine (2012)
- MD
- Albert Einstein College of Medicine (2009)
Research
Copy Link
Overview
Dr. Weiss joined the Melanoma and Renal Cell Carcinoma Disease Aligned Research Team at Yale in August 2016 and has a growing clinical practice. Her primary research interests are to develop innovative clinical trials for the management of advanced melanoma, and to identify and integrate prognostic and predictive biomarkers into clinical practice. She is currently the site Principal Investigator on several clinical trials including a study of Apexigen’s CD40 agonist in combination with nivolumab in patients with melanoma who are resistant to PD-1 immune checkpoint inhibitors. This has led to an investigator-initiated clinical trial protocol that Dr. Weiss wrote based off of preclinical work conducted in the Kaech and Bosenberg laboratories here at Yale, aimed at overcoming resistance to PD-1/PD-L1 agents by targeting both the innate and adaptive immune systems with a triple combination of a CD40 agonist, CSF1R inhibitor, and PD-1 inhibitor.
Medical Research Interests
Immunotherapy; Melanoma
Public Health Interests
Cancer
ORCID
0000-0002-1106-7089
Research at a Glance
Yale Co-Authors
Frequent collaborators of Sarah Weiss's published research.
Publications Timeline
A big-picture view of Sarah Weiss's research output by year.
Research Interests
Research topics Sarah Weiss is interested in exploring.
Harriet Kluger, MD
Thuy Tran, MD, PhD
Kelly Olino, MD, FACS
Mario Sznol, MD
Veronica Chiang, MD, FAANS
Amit Mahajan, MD
58Publications
2,182Citations
Publications
2025
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Yang J, Wang C, Fu D, Ho L, Galani K, Chen L, Gonzalez J, Fu J, Huang A, Frederick D, He L, Asnani M, Tacke R, Robitschek E, Yadav S, Deng W, Burke K, Sharova T, Sullivan R, Weiss S, Rai K, Liu D, Boland G, Kellis M. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nature Communications 2025, 16: 8151. PMID: 40890106, PMCID: PMC12402436, DOI: 10.1038/s41467-025-62878-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune checkpoint inhibitorsProgression-free survivalDendritic cellsTumor microenvironmentAnti-PD-1 checkpoint blockadeTranscriptional hallmarksCD8 T-cell ratiosT-and B-cellsAnti-PD-1 therapyDendritic cell subtypesT cell ratioConventional dendritic cellsMigratory dendritic cellsMetastatic melanoma samplesCheckpoint blockadeCheckpoint inhibitorsMetastatic melanomaImmunotherapy responsePredictive biomarkersImmune infiltrationMalignant cellsB cellsImmunoregulatory moleculesIndependent cohortMelanoma samplesCase Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab
Palmeri M, Weiss S, Purnell P. Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab. Frontiers In Oncology 2025, 15: 1615835. PMID: 40936685, PMCID: PMC12420325, DOI: 10.3389/fonc.2025.1615835.Peer-Reviewed Original ResearchCitationsConceptsImmune-related adverse eventsImmune checkpoint inhibitorsMetastatic melanoma treated with ipilimumabRare immune-related adverse eventImmune checkpoint inhibitors rechallengeMelanoma treated with ipilimumabMetastatic mucosal melanomaResponse to steroidsStandard of careNivolumab monotherapyCheckpoint inhibitorsAdvanced melanomaMucosal melanomaAirway compromiseSupraglottic edemaAdverse eventsAirway obstructionGlobus sensationClinical challengeAirway diseaseEarly recognitionLaryngoscopic evaluationSupraglottitisNivolumabMelanomaPhase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchCitationsConceptsMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-Transit MelanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsMetastatic Merkel Cell Carcinoma Incidentally Detected on PSMA PET/CT in a Patient With Metastatic Prostate Cancer
Raynor W, Ranpariya M, Kempf J, Saraiya B, Weiss S. Metastatic Merkel Cell Carcinoma Incidentally Detected on PSMA PET/CT in a Patient With Metastatic Prostate Cancer. Case Reports In Radiology 2025, 2025: 1751973. PMID: 41210275, PMCID: PMC12595225, DOI: 10.1155/crra/1751973.Peer-Reviewed Original ResearchConceptsProstate-specific membrane antigenMerkel cell carcinomaMetastatic Merkel cell carcinomaPositron emission tomographyCell carcinomaProstate cancerProstate-specific membrane antigen PET/CTProstate-specific membrane antigen uptakeEvaluation of prostate cancerInguinal lymph node metastasisMetastatic prostate adenocarcinomaMetastatic prostate cancerLymph node metastasisNonprostatic malignanciesSynchronous malignanciesDiagnostic biopsyProstatic adenocarcinomaNode metastasisTumor neovasculatureMembrane antigenClinical historyTreatment planningEmission tomographyCarcinomaMalignancy
2024
Patterns of brain metastases response to immunotherapy with pembrolizumab
Mahajan A, Goldberg S, Weiss S, Tran T, Singh K, Joshi K, Aboian M, Kluger H, Chiang V. Patterns of brain metastases response to immunotherapy with pembrolizumab. Journal Of Neuro-Oncology 2024, 169: 555-561. PMID: 38963658, DOI: 10.1007/s11060-024-04754-8.Peer-Reviewed Original ResearchCitationsConceptsNon-small cell lung cancerBrain metastasesComplete resolutionLung cancerMedian time to CNS progressionLesion progressionNon-small cell lung cancer patientsModified RECIST criteriaPD-1 inhibitorsTrial of pembrolizumabEffective systemic treatmentResponse to immunotherapyPhase II trialCell lung cancerMethodsThis retrospective studyLocal treatment decisionsPurposeCentral nervous systemCNS progressionRECIST criteriaPD-1Local therapySystemic treatmentMRI evaluationResponse assessmentRetrospective study
2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStable diseasePartial responseMacrophage populationsThree-drug regimenUnconfirmed partial responsePhase I trialLimited treatment optionsMonocyte/macrophage populationNon-classical monocytesMurine melanoma modelTreatment-related changesResultsThirteen patientsWorse survivalI trialInflammatory tumorPatient populationTreatment optionsImmune cellsDisease progressionMurine studiesPreclinical modelsResistant melanomaAntigen presentationMurine modelCyTOF analysisUse of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
Ji S, Liu H, Pachella L, Stephenson R, Groisberg R, Weiss S. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Frontiers In Transplantation 2023, 2: 1284740. PMID: 38993910, PMCID: PMC11235332, DOI: 10.3389/frtra.2023.1284740.Peer-Reviewed Original ResearchCitationsAltmetricConceptsImmune checkpoint inhibitorsCutaneous squamous cell carcinomaObjective response rateMerkel cell carcinomaSolid organ transplant recipientsOrgan transplant recipientsSOT recipientsGraft rejectionCutaneous malignanciesCheckpoint inhibitorsTransplant recipientsCell carcinomaRetrospective analysisFirst-line immune checkpoint inhibitorsPrior systemic therapyAdvanced skin cancerSquamous cell carcinomaAdvanced cutaneous malignanciesImmunosuppressive therapyAllograft rejectionGraft failureSystemic therapyAdvanced melanomaCare therapyImmunosuppressive agentsSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, Hieken T, Izar B, Johnson D, Kulkarni R, Luke J, Mitchell T, Mooradian M, Rubin K, Salama A, Shirai K, Taube J, Tawbi H, Tolley J, Valdueza C, Weiss S, Wong M, Sullivan R. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal For ImmunoTherapy Of Cancer 2023, 11: e006947. PMID: 37852736, PMCID: PMC10603365, DOI: 10.1136/jitc-2023-006947.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune checkpoint inhibitorsClinical practice guidelinesCutaneous melanomaTreatment of melanomaPractice guidelinesProlongs recurrence-free survivalCancer clinical practice guidelinesCell death protein 1Metastatic cutaneous melanomaBispecific T cell engager (BiTE) therapyChemotherapy-resistant diseaseRecurrence-free survivalDeath protein 1Long-term followManagement of patientsSpecial patient populationsImmunotherapy of cancerConsensus-based recommendationsPossibility of cureUnique toxicity profileQuality of lifeIntratumoral immunotherapyNeoadjuvant strategiesAdvanced diseaseBrain metastasesA Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1
Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Gonzalez-Cao M, Arance A, Wei W, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical Cancer Research 2023, 30: 74-81. PMID: 37535056, PMCID: PMC10767304, DOI: 10.1158/1078-0432.ccr-23-0475.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObjective response ratePhase II trialAdverse eventsPartial responseDisease progressionII trialGrade 3 adverse eventsAnti PD-1CD40 agonist antibodyElevated liver functionTreatment-related SAEsCommon adverse eventsActivation of CD40Subset of patientsFavorable safety profileAntigen presenting cellsStable diseaseMedian durationAdvanced melanomaAdditional patientsLiver functionSafety profileMetastatic melanomaPreclinical dataPresenting cells
News
Copy Link
Get In Touch
Copy Link